Material Insights · Understanding the Material World

Insulin medicines: Use case

Use cases

Each use, its share of demand and volume, how critical the product is to it and why, and the price paid

Use caseVolumeUnitCriticalityReasonYearSource
People with type 1 diabetes (world, WHO 2021)9 millionpeopleEssentialWHO: people with type 1 diabetes need insulin injections for survival.2021[1][2]
People with type 2 diabetes for whom insulin is essential (world, WHO 2021, more than)60 millionpeopleEssentialWHO says insulin is essential for them; one in two of those who need it do not get it.2021[1]
People on insulin therapy in India (type 1 and type 2, as reported)6 millionpeopleEssentialThese patients are on insulin therapy; Novo Nordisk expects 9 million users in the near future, the article says.2026[10]

as of 2026-11-13

Industries that buy it

The industries and kinds of firm that buy it, for which use case, and how critical it is to them

Used by
  • Healthcare services Treatment of diabetes · criticality essential Clinics, hospitals and pharmacies supply insulin to patients, who inject it themselves; no share found.

as of 2026-11-13

How it is used

Lifetime, use per year and utilisation, by variant

MeasureValueUnitPlaceYearSource
Pens used per patient in a year, once-daily basal insulin (modelled by authors from Novo Nordisk and Putnam)22pens per yearFrance2024[14]
Pens used per patient in a year, once-weekly basal insulin (modelled by authors from Novo Nordisk and Putnam)5pens per yearFrance2024[14]
People on insulin therapy (as reported in the press, roughly)6million peopleIndia2026[10]
People living with diabetes, all types and treatments830million peopleWorld2022[2]

as of 2026-11-13

Prices

Unit prices by market or use, with year and source

MarketValueUnitYearSource
US manufacturer gross price per 100 IU as a multiple of the price in 33 OECD comparison countries combined9.71times2022[9]
US net price per 100 IU after estimated gross-to-net discounts, as a multiple of the price in the comparison countries combined2.33times2022[9]
Analogue insulins against human insulins, at least (WHO; in some countries three times)1.5times the price2021[1]
Biosimilar insulins against the originator product, could be cheaper by more than25%2021[1]
Awiqli (once-weekly insulin), 1 ml pen, India (as reported by BioSpectrum India; not confirmed from an official price list)2611INR2026[10]
Awiqli, 3 ml pen, India (as reported by BioSpectrum India; not confirmed from an official price list)7833INR2026[10]
Once-weekly 70-unit dose of Awiqli, India, against Rs 345 to Rs 453 for 70 units of daily basal insulin (the company's own comparison, as reported)261INR2026[10]

as of 2026-11-13

Sources

  1. New WHO report maps barriers to insulin availability and suggests actions to promote universal access World Health Organization, 2021, news item of 12 November 2021
  2. Diabetes (fact sheet) World Health Organization, 2026, fact sheet dated 11 November 2026
  3. Comparing Insulin Prices in the United States to Other Countries: Updated Results Using 2022 Data RAND Health Quarterly (Andrew W. Mulcahy and Daniel Schwam), 11(3):3, 2024, abstract and summary
  4. India 2030: Who Supplies the Next 10 Million? BioSpectrum India (Ankit Kankar), 2026, article of 1 November 2026
  5. Environmental Impact of Switching from Daily to Weekly Basal Insulin Administration in France ISPOR Europe 2024 abstract EE212 (Bellier L, Antier C, Soggiu M, Virely N, Laporte L, Sivignon M, Kind B; affiliations Putnam, Paris, and Novo Nordisk, Paris), Value in Health 27(12) S2, 2024